Lead Product(s) : SNIPR001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : INDA approval is based on the positive pre-clinical data for SNIPR001 which showed that it holds a huge potential against life-threatening infections and also in modulating microbiome-associated diseases.
Product Name : SNIPR001
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 01, 2022
Lead Product(s) : SNIPR001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable